Search

everythinglearnresearchcommunity

for

Search:↓

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.

2-deoxy D-glucose does not help with hair regrowth in alopecia areata.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.